Moderna – at the moment embroiled in a patent dispute with Pfizer and BioNTech over mRNA intellectual property – is also testing a vaccine that combines COVID-19 and flu in a single jab in a ...
Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...
BioNTech, the German developer of a widely used mRNA vaccine for the coronavirus, agreed to pay US$800 million (HK$6.24 billion) to buy biotech company Biotheus, a developer of cancer drugs. In ...
Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall and winter seasons. Here we answer common questions about the latest ...
Hosted on MSN5d
Should Kids Get the COVID-19 Vaccine?Novavax is approved for children aged 12 and older. Both Moderna and Pfizer-BioNTech vaccines use messenger RNA (mRNA), ...
Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled. A ...
With this in mind, is the luster of mRNA companies like BioNTech and Moderna gone? Are they one-trick ponies who found tremendous success only with COVID vaccines? Is either one worth investing ...
Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...
Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...
Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback